JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.

JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients.
Acta Haematol. 2020 Jul 29;:1-5
Authors: Rojas P, Sarmiento M
Abstract
COVID-19 has rapidly become a major concern for the health systems worldwide. Its high contagiousness and associated mortality demand the discovery of helpful interventions with promising safety profile. Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of ruxolitinib, a JAK/STAT pathway inhibitor.
PMID: 32726783 [PubMed - as supplied by publisher]

Source: Acta Haematologica - July 28, 2020 Category: Hematology Authors: Rojas P, Sarmiento M Tags: Acta Haematol Source Type: research